StreetInsider.com News Articles

Lonza unit Synaffix licenses ADC platform to Sidewinder Therapeutics

Wed, 07 Jan 2026 03:30:14 -0500

Synaffix B.V., a Lonza company (SWX: LONN), entered into a multi-target licensing agreement with Sidewinder Therapeutics to develop bispecific antibody-drug conjugates for solid tumor treatments, the companies announced January 7.

The agreement grants Sidewinder access to Lonza's ADC technology platform, including GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, and toxSYN linker payload systems. Sidewinder will use these components to develop bispecific ADCs targeting tumor-specific receptor complexes.

Under the terms, Lonza is eligible to receive upfront, clinical, regulatory and commercial milestone payments plus royalties on net sales of resulting products. Lonza will manufacture components related to its proprietary technologies, while Sidewinder handles

Lonza unit Synaffix licenses ADC platform to Sidewinder Therapeutics

Wed, 07 Jan 2026 03:30:14 -0500

Lonza unit Synaffix licenses ADC platform to Sidewinder Therapeutics

Wed, 07 Jan 2026 03:30:14 -0500

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Wed, 07 Jan 2026 03:30:00 -0500

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform
Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications

AMSTERDAM and SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Sidewinder Therapeutics, a precision ADC therapeutics company with a pipeline of bispecific antibodies with enhanced tumor-cell specificity and internalization,

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Wed, 07 Jan 2026 03:30:00 -0500

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform
Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Wed, 07 Jan 2026 03:30:00 -0500

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform
Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Wed, 07 Jan 2026 03:30:00 -0500

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform
Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Wed, 07 Jan 2026 03:30:00 -0500

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform
Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Wed, 07 Jan 2026 03:30:00 -0500

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform
Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ADC platform will enable the development of first-in-class bispecific ADCs with enhanced tumor-cell internalization to treat solid tumor indications

Lonza confirms "long-term commercial supply agreement" at U.S. biologic drug site

Thu, 23 Oct 2025 07:03:46 -0500

Investing.com - Shares of Lonza spiked in early European trading on Thursday after the Swiss contract pharmaceutical firm confirmed a "significant" long-term commercial supply agreement at one of the world’s largest manufacturing sites for biologic drugs in the United States.

In a statement, Lonza added that the site in the California city of Vacaville, which it acquired from peer Roche in 2024 for $1.2 billion, had experienced "sustained high customer interest."

Lonza said integration of the facility into its global network was "progressing fully in line with plan," showing "strong and consistent operational execution" while "maintaining its excellent quality track record" and "advancing

Lonza confirms "long-term commercial supply agreement" at U.S. biologic drug site

Thu, 23 Oct 2025 07:03:46 -0500

In a statement, Lonza added that the site in the California city of Vacaville, which it acquired from peer Roche in 2024 for $1.2 billion, had experienced "sustained high customer interest."

Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC

Thu, 25 Sep 2025 03:30:00 -0500

License agreement centered around technology enabling dual-payload ADC
Unique combination of Synaffix's exatecan-based technology with Qurient's CDK7 inhibitor

AMSTERDAM and SEONGNAM-SI, South Korea , Sept. 25, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly announced that it has entered into a licensing agreement with Qurient Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, for the development of a dual-payload ADC.

Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct

Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC

Thu, 25 Sep 2025 03:30:00 -0500

License agreement centered around technology enabling dual-payload ADC
Unique combination of Synaffix's exatecan-based technology with Qurient's CDK7 inhibitor

Dual-payload ADCs are designed to deliver two separate cytotoxic agents with distinct

HSBC shuffles MedTech stocks, cutting 4, upgrading 2

Fri, 25 Apr 2025 09:09:36 -0500

Investing.com -- HSBC has reshuffled its ratings across the MedTech and Life Sciences sector, upgrading Siemens Healthineers AG (ETR:SHLG) and Sonova (SIX:SOON) to Buy while cutting Align Technology (NASDAQ:ALGN), Eurofins Scientific SE (EPA:EUFI), IQVIA, and Smith&Nephew (LON:SN) to Hold.